Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
NCT06375564
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Refractory Solid Tumor
Interventions
DRUG:
177Lu-AB-3PRGD2 radioligand therapy
Sponsor
The First Affiliated Hospital of Xiamen University